- Home
- CIM vs PHAT Comparison
CIM vs PHAT Comparison
Compare CIM & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- PHAT
- Stock Information
- Founded
- CIM 2007
- PHAT 2018
- Country
- CIM United States
- PHAT United States
- Employees
- CIM N/A
- PHAT N/A
- Industry
- CIM Real Estate Investment Trusts
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- PHAT Health Care
- Exchange
- CIM Nasdaq
- PHAT Nasdaq
- Market Cap
- CIM 1.2B
- PHAT 1.2B
- IPO Year
- CIM 2007
- PHAT 2019
- Fundamental
- Price
- CIM $14.62
- PHAT $9.45
- Analyst Decision
- CIM Hold
- PHAT Strong Buy
- Analyst Count
- CIM 2
- PHAT 4
- Target Price
- CIM $16.25
- PHAT $22.50
- AVG Volume (30 Days)
- CIM 518.2K
- PHAT 1.9M
- Earning Date
- CIM 11-06-2024
- PHAT 11-07-2024
- Dividend Yield
- CIM 10.10%
- PHAT N/A
- EPS Growth
- CIM 117.60
- PHAT N/A
- EPS
- CIM 3.36
- PHAT N/A
- Revenue
- CIM $442,341,000.00
- PHAT $26,270,000.00
- Revenue This Year
- CIM N/A
- PHAT $6,714.96
- Revenue Next Year
- CIM $10.28
- PHAT $293.69
- P/E Ratio
- CIM $4.36
- PHAT N/A
- Revenue Growth
- CIM 44.27
- PHAT N/A
- 52 Week Low
- CIM $11.29
- PHAT $6.07
- 52 Week High
- CIM $16.89
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- CIM 39.07
- PHAT 30.83
- Support Level
- CIM $14.41
- PHAT $8.55
- Resistance Level
- CIM $15.48
- PHAT $19.05
- Average True Range (ATR)
- CIM 0.36
- PHAT 1.68
- MACD
- CIM -0.04
- PHAT -0.65
- Stochastic Oscillator
- CIM 28.33
- PHAT 8.68
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.